[go: up one dir, main page]

PE20100746A1 - Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables - Google Patents

Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables

Info

Publication number
PE20100746A1
PE20100746A1 PE2009001300A PE2009001300A PE20100746A1 PE 20100746 A1 PE20100746 A1 PE 20100746A1 PE 2009001300 A PE2009001300 A PE 2009001300A PE 2009001300 A PE2009001300 A PE 2009001300A PE 20100746 A1 PE20100746 A1 PE 20100746A1
Authority
PE
Peru
Prior art keywords
camptotechin
biocompatible
biodegradable
pharmaceutical formulations
polymer conjugates
Prior art date
Application number
PE2009001300A
Other languages
English (en)
Inventor
James Rolke
Russell C Petter
Mao Yin
Emile Farhan
Aleksandr Yurkovetskiy
Gui Liu
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42243068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of PE20100746A1 publication Critical patent/PE20100746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTOS DE FORMULA I, DONDE R1 ES H, -C(O)-CH2-CH2-C(O)-OH Y EL OTRO ES -CO-CH2-CH2-C(O)-NH-CH2-C(O)-OCPT; R2 ES H, -C(O)-CH2-CH2-C(O)-OH; CPT ES CAMPTOTECINA; n ES 32-3320; m ES 0-833; k ES 1-216, DONDE k, m Y n SE SELECCIONAN DE MODO TAL QUE APROXIMADAMENTE 1-15% DEL COMPUESTO EN PESO ES CAMPTOTECINA; B) UN AGENTE DE ESTABILIZACION SELECCIONADO ENTRE SORBITOL, MANITOL, SACAROSA, LACTOSA, GLUCOSA, XILITOL, ENTRE OTROS; C) UNO O VARIOS TAMPONES SELECCIONADOS ENTRE CITRATO DE SODIO, ASCORBATO, GLICINA, EDTA, 3-(N-MORFOLINO)PROPANSULFONICO; D) UN TENSIOACTIVO SELECCIONADO ENTRE POLISORBATO 80, POLOXAMER 407, SOLUTOL HS 15, CLORURO DE BENZALCONIO. DICHA FORMULACION ES UNA TORTA LIOFILIZADA APROPIADA PARA ADMINISTRACION ENDOVENOSA UTIL EN EL TRATAMIENTO ANTINEOPLASICO Y ANTITUMORAL
PE2009001300A 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables PE20100746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12138408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
PE20100746A1 true PE20100746A1 (es) 2010-11-04

Family

ID=42243068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001300A PE20100746A1 (es) 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables

Country Status (9)

Country Link
US (2) US8491880B2 (es)
KR (1) KR20110102420A (es)
CN (1) CN102307473A (es)
AR (1) AR074584A1 (es)
CL (1) CL2009002167A1 (es)
PA (1) PA8853201A1 (es)
PE (1) PE20100746A1 (es)
TW (1) TW201036639A (es)
WO (1) WO2010068759A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794307A1 (en) * 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20180157397A1 (en) * 2016-04-08 2018-06-07 Maxx Media Group, LLC System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display
CN109563215B (zh) * 2016-06-03 2021-11-19 诺灵生物医药科技(北京)有限公司 聚合物连接子及其用途
JP7261158B2 (ja) 2016-10-19 2023-04-19 インベンラ， インコーポレイテッド 抗体構築物
CN110291107B (zh) 2016-12-22 2023-05-05 卡坦扎罗麦格纳格拉西亚大学 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体
CA3066754A1 (en) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
CN120795120A (zh) 2018-06-05 2025-10-17 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793986A (en) 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
JPH01190636A (ja) 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
JPH07509467A (ja) * 1992-07-21 1995-10-19 ザ　ゼネラル　ホスピタル　コーポレーション リンパ組織への薬物輸送システム
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP0821001A4 (en) * 1995-03-31 2002-07-17 Drug Delivery System Inst Ltd AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
PT932399E (pt) 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
NZ515999A (en) 1999-06-18 2004-03-26 Ml Lab Plc Biologically active materials
IL131074A0 (en) 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
EP1206285A2 (en) 1999-08-09 2002-05-22 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
EP1315777B1 (en) * 2000-09-06 2007-10-31 AP Pharma, Inc. Degradable polyacetal polymers
DE60323936D1 (de) * 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
DE60329126D1 (de) * 2002-02-20 2009-10-15 Beth Israel Hospital Konjugate mit biologisch abbaubarem polymer und verwendung dafür
AU2003254023A1 (en) 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
WO2004009774A2 (en) 2002-07-19 2004-01-29 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
PT1534340E (pt) * 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
EP1608380A2 (en) 2003-03-31 2005-12-28 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
EP1667726B1 (en) * 2003-09-05 2011-05-04 The General Hospital Corporation Polyacetal drug conjugates as release system
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
CN101641285B (zh) * 2007-01-31 2012-10-10 中央电气工业株式会社 碳材料及其制造方法
EA020251B1 (ru) * 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
WO2010144881A1 (en) 2009-06-12 2010-12-16 The General Hospital Corporation Treatment of meningeal and neural diseases

Also Published As

Publication number Publication date
US8491880B2 (en) 2013-07-23
TW201036639A (en) 2010-10-16
CN102307473A (zh) 2012-01-04
WO2010068759A1 (en) 2010-06-17
AR074584A1 (es) 2011-01-26
PA8853201A1 (es) 2010-07-27
CL2009002167A1 (es) 2010-10-15
US20140004074A1 (en) 2014-01-02
KR20110102420A (ko) 2011-09-16
US20100179181A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
PE20100746A1 (es) Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables
ECSP088239A (es) Composición de liberación de fármaco sostenida
ECSP088240A (es) Composición de trazodona para administración una vez por día
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
HRP20110444T1 (hr) Formulacije paratiroidnih hormona i njihove uporabe
AR056609A1 (es) Composiciones estabilizadas de carbonato de lantano
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
PE20071243A1 (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
ECSP105163A (es) Composiciones farmaceuticas de agonista parcial de 5ht4
PE20070210A1 (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c
NZ593190A (en) Factor viii formulations
ES2282062T1 (es) Composicion farmaceutica que contiene irbesartan.
AR106776A1 (es) Composiciones de cuidado oral
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
MX2025003905A (es) Tiosulfato de sodio anhidro y formulaciones de este
ECSP077262A (es) Composicion antihistaminica
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
PE20090387A1 (es) Formulacion de pasireotida
AR062979A1 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
AR072333A1 (es) Composiciones inyectables a base de taxoides
AR059113A1 (es) Composicion para administracion topica

Legal Events

Date Code Title Description
FD Application declared void or lapsed